---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037582"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:31:59.699502+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InfuSystem Q2 net revenue $36M (+7% YoY); net income up 262% to $2.6M; raises FY25 EBITDA margin guidance to 20%+

## Summary
- Net revenue $36.0M (+7% YoY); Patient Services $21.5M (+6%), Device Solutions $14.5M (+8%).
- Net income $2.6M ($0.12 diluted EPS) vs $0.7M ($0.03) prior year; Adjusted EBITDA $8.0M (+32%).
- Gross margin expanded 5.7 pts to 55.2%; YTD operating cash flow $8.8M (up 227%).
- FY25 revenue growth guidance lowered to 6-8% (from 8-10%), but Adjusted EBITDA margin raised to 20%+ (from 18.8%+).
- Repurchased $3.5M of stock in Q2; acquired a small company for $1.4M to improve Advanced Wound Care processing.

## SEC filing metadata
- accession: 0001628280-25-037582
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828025037582/0001628280-25-037582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828025037582/infu-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037582
- JSON: https://secwatch.observer/filing/0001628280-25-037582.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.